Victory Capital Management
EPZM

Victory Capital Management’s Epizyme, Inc EPZM Stock Holding History

Victory Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,287
Closed -$22K – 2835
2022
Q2 		$22K Sell
15,287
-3,556
-19% -$2.61K ﹤0.01% 2611
2022
Q1 		$12K Buy
18,843
+8,263
+78% +$13.5K ﹤0.01% 2675
2021
Q4 		$26K Sell
10,580
-156
-1% -$613 ﹤0.01% 2684
2021
Q3 		$55K Sell
10,736
-352
-3% -$2.14K ﹤0.01% 2680
2021
Q2 		$92K Sell
11,088
-488
-4% -$4.11K ﹤0.01% 2610
2021
Q1 		$101K Sell
11,576
-2,656,401
-100% -$27.5M ﹤0.01% 2605
2020
Q4 		$29M Sell
2,667,977
-97,315
-4% -$1.2M 0.03% 725
2020
Q3 		$33M Buy
2,765,292
+469,182
+20% +$6.28M 0.04% 600
2020
Q2 		$36.9M Buy
2,296,110
+118,026
+5% +$2.06M 0.05% 534
2020
Q1 		$33.8M Sell
2,178,084
-468,584
-18% -$10.1M 0.06% 477
2019
Q4 		$65.1M Buy
2,646,668
+470,980
+22% +$6.99M 0.08% 372
2019
Q3 		$22.4M Buy
2,175,688
+494,858
+29% +$6.24M 0.03% 755
2019
Q2 		$21.1M Buy
1,680,830
+43,360
+3% +$558K 0.04% 601
2019
Q1 		$20.3M Buy
+1,637,470
New +$18.3M 0.05% 566

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Victory Capital Management's EPZM Position: Q3 2022 in Review

Victory Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 15,287 shares — an estimated $22K sold.

Victory Capital Management first reported a position in EPZM in Q1 2019 and held it in 14 quarters. The position peaked at $65.1M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • Victory Capital Management reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • Victory Capital Management sold 15,287 Epizyme, Inc shares in Q3 2022, an estimated $22K.
  • Victory Capital Management first reported a position in Epizyme, Inc in Q1 2019 and held it in 14 quarters.
  • Victory Capital Management's Epizyme, Inc position peaked at $65.1M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.